Design, synthesis and evaluation of 2-(4-(substituted benzoyl)-1,4-diazepan-1-yl)-N-phenylacetamide derivatives as a new class of falcipain-2 inhibitors  by Mahesh, Radhakrishnan et al.
Arabian Journal of Chemistry (2014) xxx, xxx–xxxKing Saud University
Arabian Journal of Chemistry
www.ksu.edu.sa
www.sciencedirect.comORIGINAL ARTICLEDesign, synthesis and evaluation of
2-(4-(substituted benzoyl)-1,4-diazepan-1-yl)-
N-phenylacetamide derivatives as a new class
of falcipain-2 inhibitors* Corresponding author at: Department of Pharmacy, FD-3, Birla
Institute of Technology & Science, Pilani 333031, Rajasthan, India.
Fax: +91 01596244183.
E-mail address: sourabh_mundra@yahoo.co.in (S. Mundra).
Peer review under responsibility of King Saud University.
Production and hosting by Elsevier
http://dx.doi.org/10.1016/j.arabjc.2014.11.008
1878-5352 ª 2014 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Please cite this article in press as: Mahesh, R. et al., Design, synthesis and evaluation of 2-(4-(substituted benzoyl)-1,4-diazepan-1-yl)- N-phenylacetamide de
as a new class of falcipain-2 inhibitors. Arabian Journal of Chemistry (2014), http://dx.doi.org/10.1016/j.arabjc.2014.11.008Radhakrishnan Mahesh a, Sourabh Mundra a,*, Thangaraj Devadoss a,
Lakshmi P. Kotra ba Department of Pharmacy, FD-3, Birla Institute of Technology & Science, Pilani 333031, Rajasthan, India
b Centre for Molecular Design and Preformulations, University Health Network, Toronto, CanadaReceived 4 July 2014; accepted 3 November 2014KEYWORDS
Malaria;
Plasmodium falciparum;
Structure–activity relation-
ships (SARs);
Ligand-based drug design;
Antimalarial agentsAbstract The cysteine protease, falcipain-2 is an important drug target in human malaria parasite
Plasmodium falciparum. A new series of 2-(4-(substituted benzoyl)-1,4-diazepan-1-yl)-N-phenylacet-
amide derivatives 5(a–t) were designed as per pharmacophoric requirements of falcipain-2 inhibi-
tors using ligand-based approach. The target compounds were synthesized from the key
intermediate, 2-(1,4-Diazepan-1-yl)-N-phenylacetamide, by coupling it with appropriate carboxylic
acids using carbodiimide chemistry. Structural features of target compounds were characterized by
spectral data (1H NMR, and mass) and elemental analyses. The purity of the ﬁnal compounds was
conﬁrmed by HPLC. The compounds were tested for their in vitro falcipain-2 inhibitor activity on
recombinant falcipain-2 enzyme. Five compounds 5b, 5g, 5h, 5j, 5k showed good inhibitory activity
(>60%), against falcipain-2 at 10 lM concentration, and ﬁfteen compounds showed weak to mod-
erate inhibitor activity. Compound 5g, the most potent compound from this series showed 72%
inhibition at 10 lM concentrations.
ª 2014 TheAuthors. Production and hosting by Elsevier B.V. on behalf of King SaudUniversity. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
The increasing ratio of malaria in terms of morbidity and mor-
tality in humans turns it into a major public health problem in
tropical and subtropical countries. World Health Organization
Malaria report 2012 indicates that in 2010, there were 219 mil-
lion malaria cases leading to approximately 660,000 malaria
deaths, mostly among African children. Out of reported 90%
malaria casualties in Africa alone the majority were childrenrivatives
2 R. Mahesh et al.under ﬁve (Vangapandu et al., 2007). Globally, 80% of
malaria deaths occur in just 14 African countries. Together,
the Democratic Republic of the Congo and Nigeria account
for over 40% of the estimated total of malaria death world-
wide (World Malaria Report, 2012). Rapid spread of resis-
tance is becoming most apparent in Plasmodium falciparum
species toward ﬁrst-line treatment, chloroquine and sulfadox-
ine-pyrimethamine (Marfurt et al., 2010). To enhance the
efﬁcacy and delayed onset of resistance, the WHO began rec-
ommending for use of Artemisinin based combination thera-
pies (ACTs) since 2005 (Rogerson and Menendez, 2006).
ACTs have potential clinical efﬁcacy, paradoxically the history
of antimalarial chemotherapy predicts that it is a matter of
time before parasitic resistance emerges and spreads (Ekland
and Fidock, 2008). Nevertheless, safe and cost effective novel
chemical classes of antimalarial agents are urgently needed
to treat malaria (Guerin et al., 2002).
Among various potential new targets, the cysteine protease
falcipain-2 (FP-2) of P. falciparum is the most intensely studied
enzyme, and its structural and functional data suggest that it is
an attractive target for therapeutic intervention (Pandey et al.,
2005; Wang et al., 2006). FP-2 is a principal cysteine protease
that plays a major role in parasite food assimilation by its abil-
ity to degrade hemoglobin. Many in vitro studies have afﬁrmed
that inhibitors of falcipain-2 can inhibit the parasite hemoglo-
bin hydrolysis and prevent the growth of culture parasites
(Shenai et al., 2003; Lee et al., 2003; Domı´nguez et al., 1997;
Huang et al., 2002). Some of them were also effective against
murine malaria in vivo (Domı´nguez et al., 2005; Rosenthal
et al., 1993; Sajid and McKerrow, 2002). However, the litera-
ture indicates that most of the reported FP-2 inhibitors are
mainly derived from peptide analogues (Choi et al., 2013;
Mallik et al., 2012; Schulz et al., 2007; Schirmeister and
Kaeppler, 2003; Shenai et al., 2003; Lee et al., 2003), which
have expressed nanomolar IC50 values, due to the formation
of covalent interactions between the electrophilic groups, such
as aldehydes, nitriles, vinyl sulfones and epoxides with thiolate
of the catalytic cysteine amino acid. In addition, most of the
existing standard ligands for falcipain-2, and cystine protease
inhibitors such as Leupeptin (N-acetyl-L-leucyl-L-leucyl-L-
argininal) (Moldoveanu et al., 2004), and E-64 (N-(trans-
epoxysuccinyl)-L-leucine 4-guanidinobutylamide) (Moldoveanu
et al., 2004; Varughese et al., 1989) possess chiral center(s),
(Fig. 1) which increases the synthetic cost of these drugs.
This discussion clearly stresses the requirements of
non-peptidic inhibitors that would bind non-covalently to
the target enzyme in order to reduce toxicity and cost while
retaining the potential for high activity and selectivity. The
present study demonstrates the design, synthesis and in vitroHO O
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phenylacetamides as falcipain-2 inhibitors. Compounds 5(a–t)
were synthesized through the route outlined in Scheme 1. Fur-
thermore, docking studies were performed for the active com-
pounds to predict their relative binding afﬁnities and binding
modes in the active site of the falcipain-2 enzyme. Molecular
docking studies of most active analogues (5g, 5h, 5j, and 5k)
revealed that they interacted with Gln 36, Gln 83, Asn 173
and Hip 174 residues of 3BPF protein, via hydrogen bonding.
Moreover, in silico pharmacokinetics and toxicity (ADMET)
parameters for the selected analogues were estimated using
online tool admetSAR and QikProp module of Schrodinger.
2. Materials and methods
2.1. General
Melting points (m.p.) were determined in open capillary tubes
and on a Buchi 530 melting point apparatus and were uncor-
rected. Thin layer chromatography (TLC) was performed to
monitor progress of the reaction and assess purity of the com-
pounds; spots were detected by their absorption under UV
light. 1H NMR, spectra were recorded with Bruker DPX oper-
ating at 400 MHz in CDCl3 or DMSO-d6 solvent, with tetra-
methylsilane (TMS) as an internal standard. Chemical shifts
are shown as d values (ppm); the J values are expressed in
Hertz (Hz). Signals are represented as s (singlet), d (doublet),
t (triplet), q (quintet) or m (multiplet). Mass spectra (ESI) of
most of the compounds exhibited molecular ion as (M+1)+/
(M+Na)+. Purity of ﬁnal compounds 5(a–t) was evaluated
on a Waters LC/MS system equipped with a photodiode
array detector using an XBridge C18 5 lm 4.6 mm · 150 mm
column. The methods used were of three types. Method A:
15% MeOH in H2O (1 mL/min, isocratic), Method B: 25%
MeOH in H2O (1 mL/min, isocratic), and Method C: 20%
CH3CN (0.05% TFA) in H2O (1 mL/min, isocratic). Elemen-
tal analysis was performed on a PE-2400 elemental analyzer;
the C, H and N analysis was repeated twice. The chemicals
were purchased commercially from Aldrich, Fluka, and
Spectrochem.
2.2. Synthesis of 2-chloro-N-phenylacetamide (2)
In a round bottom ﬂask (500 mL), compound 1 (1 g,
10.7 mmol) and triethylamine (2.9 mL, 21.4 mmol) were sus-
pended in anhydrous DCM (200 mL) and cooled to 0 C. To
this chloroacetylchloride (1.7 mL, 21.4 mmol) was added.
The reaction mixture was then stirred at room temperatureN
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Scheme 1 Synthetic route for target compounds 5(a–t). Reagents and conditions: (i): Chloroacetylchloride, TEA, DCM, 0 C-RT,
20 min; (ii): N-Boc-homopiperazine, K2CO3, CH3CN, 100 C, 5 h.; (iii): TFA/DCM, 0 C-RT, 6 h; (iv): Various carboxylic acids,
EDCÆHCl, HOBt/DIPEA-DCM, 0 C-RT, 6 h.
Synthesis of 2-(4-(substituted benzoyl)-1,4-diazepan-1-yl)-N-phenylacetamide derivatives 3for 20 min; quenched with saturated sodium hydrogen carbon-
ate (10 ml) and washed with water. The organic layer was sep-
arated and dried over sodium sulfate. The organic layer was
evaporated under reduced pressure, and the crude reaction
mixture was puriﬁed by column chromatography using
chloroform and methanol as a mobile phase to obtain a pure
compound 2 as a white solid. Yields 66%, 1H NMR
(400 MHz, CDCl3) d: 8.18 (s, 1H), 7.47 (d, J= 8.0 Hz, 2H),
7.28 (t, J= 8.0 Hz, 2H), 7.10 (t, J= 8.0 Hz, 1H), 4.12 (s, 2H).
2.3. Synthesis of tert-butyl 4-(2-oxo-2-(phenylamino)ethyl)-
1,4-diazepane-1-carboxylate (3)
To a solution of compound 2 (1.0 g, 5.8 mmol), K2CO3 (4.0 g,
29.4 mmol), in anhydrous acetonitrile (10 ml) was stirred for
10 min at 100 C. To the above solution N-Boc-homopiper-
azine (1.4 ml, 7.0 mmol) was added and reﬂuxed for 5 h. Com-
pletion of the reaction was monitored by TLC. Acetonitrile
was removed under vacuum, and the reaction crude was
diluted with ethyl acetate. The organic layer was then washed
with water, dried over anhydrous sodium sulfate and evapo-
rated under vacuum to get a crude mixture which was puriﬁed
by column chromatography using chloroform and methanol as
a mobile phase to obtain a pure compound 3 as a brown solid.
Yields 68%, 1H NMR (CDCl3) d: 9.16 (s, 1H), 7.51
(d, J= 8.0 Hz, 2H), 7.27 (t, J= 8.0 Hz, 2H), 7.05
(t, J= 8.0 Hz, 1H), 3.52 (s, 2H), 3.45 (m, 2H), 3.25 (m, 2H),
2.79 (m, 4H), 1.84 (m, 2H), 1.40 (s, 9H).
2.4. Synthesis of 2-(1,4-diazepan-1-yl)-N-phenylacetamide (4)
To a solution of 3 (1.0 g, 3.0 mmol) in anhydrous DCM
(20 mL) in a round bottom ﬂask at 0 C, triﬂuoroacetic acid
(1.1 mL, 15.0 mmol) was added. The reaction mixture was stir-
red at room temperature for 6 h. Upon completion of the
reaction, solvent was removed under vacuum. To the residue,
saturated solution of sodium bicarbonate was added, and
extracted with ethyl acetate. Ethyl acetate portion was evapo-
rated to obtain the free amine as off white solid. Yield: 70%,
1H NMR (CDCl3) d: 9.14 (s, 1H), 7.56 (dd, J= 8.0 Hz,
1 Hz, 2H), 7.25 (m, 2H), 7.04 (m, 2H), 3.28 (s, 2H), 3.12 (m,
4H), 2.89 (m, 2H), 2.81 (m, 2H), 1.92 (m, 2H).Please cite this article in press as: Mahesh, R. et al., Design, synthesis and evaluation
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benzoyl)-1,4-diazepan-1-yl)-N-phenylacetamide derivatives
5(a–t)
To an appropriate carboxylic acid (1 g), DIPEA (2.4 equiv),
EDCÆHCl (1.5 equiv), and HOBt (0.8 equiv) in anhydrous
DCM (10 ml) were added and the reaction was stirred for
5 min at 0 C. To this reaction mixture the compound 4 (1.1
equiv) was added. The reaction was stirred for 6 h at room
temperature and then solvents were removed under reduced
pressure. The residue was dissolved in ethyl acetate, and the
organic phase was washed with 5% aqueous sodium bicarbon-
ate solution (twice) and saturated brine solution (once). The
organic layer was dried over anhydrous magnesium sulfate
and evaporated under reduced pressure, and the crude product
was puriﬁed by column chromatography.
2.5.1. 2-(4-Benzoyl-1,4-diazepan-1-yl)-N-phenylacetamide (5a)
Semi solid, purity 99% (method B); 1H NMR (CDCl3) d: 9.10
(s, 1H), 7.62 (d, J= 7.9 Hz, 1H), 7.53 (d, J= 7.9 Hz, 1H),
7.41 (d, J= 7.0 Hz, 5H), 7.33 (q, J= 7.8 Hz, 2H), 7.12 (t,
J= 7.0 Hz, 1H), 3.84 (m, 2H), 3.55 (m, 2H), 3.34 (s, 1H),
3.26 (s, 1H), 3.02 (m, 1H), 2.88 (m, 1H), 2.81 (m, 2H), 2.04
(m, 1H), 1.85 (m, 1H); MS (ESI): m/z 338.18 (M+1)+; Anal.
calcd for C20H23N3O2 C, 71.19; H, 6.87; N, 12.45; found C,
71.21; H, 6.81; N, 12.41.
2.5.2. 2-(4-(3-Fluorobenzoyl)-1,4-diazepan-1-yl)-N-
phenylacetamide (5b)
White solid, purity 97% (method B); 1H NMR (CDCl3) d: 9.09
(s, 1H), 7.61 (m, 1H), 7.50 (d, J= 7.5 Hz, 1H), 7.46 (m, 2H),
7.34 (m, 3H), 7.12 (m, 2H), 3.83 (m, 2H), 3.57 (m, 2H), 3.44 (s,
1H), 3.16 (s, 1H), 3.12 (m, 1H), 3.01 (m, 3H), 2.12 (m, 1H),
1.92 (m, 1H); MS (ESI): m/z 356.19 (M+1)+; Anal. calcd
for C20H22FN3O2 C, 67.59; H, 6.24; N, 11.82 found C,
67.61; H, 6.21; N, 11.81.
2.5.3. 2-(4-(2-Fluorobenzoyl)-1,4-diazepan-1-yl)-N-
phenylacetamide (5c)
Brown solid, purity 96% (method A); 1H NMR (CDCl3) d:
9.08 (s, 1H), 7.61 (dd, J= 8.5, 1.0 Hz, 1H), 7.55of 2-(4-(substituted benzoyl)-1,4-diazepan-1-yl)- N-phenylacetamide derivatives
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2H), 3.87 (m, 2H), 3.48 (m, 2H), 3.34 (s, 1H), 3.26 (s, 1H), 3.01
(m, 1H), 2.88 (dd, J= 6.2, 5.1 Hz, 1H), 2.81 (dd, J= 10.8,
6.7 Hz, 2H), 2.04 (m, 1H), 1.86 (m, 1H); MS (ESI): m/z
356.19 (M+1)+; Anal. calcd for C20H22FN3O2 C, 67.59; H,
6.24; N, 11.82; found C, 67.61; H, 6.21; N, 11.81.
2.5.4. 2-(4-(3-Chlorobenzoyl)-1,4-diazepan-1-yl)-N-
phenylacetamide (5d)
Semi solid, purity 95% (method A); 1H NMR (CDCl3) d: 8.99
(s, 1H), 7.61 (d, J= 7.9 Hz, 1H), 7.53 (d, J= 7.9 Hz, 1H),
7.40 (m, 2H), 7.33 (m, 4H), 7.12 (t, J= 7.2 Hz, 1H), 3.83
(m, 2H), 3.57 (m, 1H), 3.53 (t, J= 6.2 Hz, 1H) 3.37 (s, 1H),
3.28 (s, 1H), 3.04 (m, 1H), 2.85 (m, 3H), 2.06 (m, 1H), 1.89
(m, 1H); MS (ESI): m/z 371.21 (M)+ and 372.23 (M+1)+;
Anal. calcd for C20H22ClN3O2 C, 64.60; H, 5.96; N, 11.30;
found C, 64.62; H, 5.97; N, 11.31.
2.5.5. 2-(4-(4-Chlorobenzoyl)-1,4-diazepan-1-yl)-N-
phenylacetamide (5e)
Semi solid, purity 95% (method B); 1H NMR (CDCl3) d: 9.16
(s, 1H), 7.61 (d, J= 7.7 Hz, 1H), 7.52 (d, J= 7.4 Hz, 1H),
7.36 (m, 6H), 7.12 (t, J= 7.4 Hz, 1H), 3.83 (m, 2H), 3.53
(m, 2H), 3.38 (s, 1H), 3.28 (s, 1H), 3.05 (m, 1H), 2.85 (m,
3H), 2.06 (m, 1H), 1.88 (m, 1H); MS (ESI): m/z 371.21 (M)+
and 372.23 (M+1)+; Anal. calcd for C20H22ClN3O2 C,
64.60; H, 5.96; N, 11.30; found C, 64.62; H, 5.97; N, 11.31.
2.5.6. 2-(4-(2-Chlorobenzoyl)-1,4-diazepan-1-yl)-N-
phenylacetamide (5f)
Semi solid, purity 98% (method C); 1H NMR (CDCl3) d: 9.06
(s, 1H), 7.70 (d, J= 8.0 Hz, 1H), 7.62 (d, J= 7.6 Hz, 2H),
7.48 (m, 5H), 7.21 (t, J= 7.6 Hz, 1H), 3.80 (m, 2H), 3.57
(m, 2H), 3.48 (s, 1H), 3.38 (s, 1H), 3.15 (m, 1H), 3.05 (m,
3H), 2.36 (m, 1H), 1.78 (m, 1H); MS (ESI): m/z 371.21 (M)+
and 372.23 (M+1)+; Anal. calcd for C20H22ClN3O2 C,
64.60; H, 5.96; N, 11.30; found C, 64.62; H, 5.97; N, 11.31.
2.5.7. N-Phenyl-2-(4-(3-(triﬂuoromethyl)benzoyl)-1,4-
diazepan-1-yl) acetamide (5g)
White solid, purity 96% (method A); 1H NMR (CDCl3) d:
9.04 (s, 1H), 7.70 (d, J= 5.7 Hz, 2H), 7.61 (d, J= 7.8 Hz,
2H), 7.54 (dd, J= 13.9, 7.8 Hz, 2H), 7.34 (q, J= 7.8 Hz,
2H), 7.13 (m, 1H), 3.86 (m, 2H), 3.56 (m, 1H), 3.51 (t,
J= 6.4 Hz, 1H) 3.38 (s, 1H), 3.29 (s, 1H), 3.06 (m, 1H), 2.87
(m, 2H), 2.09 (m, 2H), 1.90 (m, 1H); MS (ESI): m/z 406.21
(M+1)+; Anal. calcd for C21H22F3N3O2 C, 62.21; H, 5.47;
N, 10.36; found C, 62.22; H, 5.45; N, 10.35.
2.5.8. N-Phenyl-2-(4-(4-(triﬂuoromethyl)benzoyl)-1,4-
diazepan-1-yl)acetamide (5h)
Yellow solid, purity 95% (method A); 1H NMR (CDCl3) d:
9.04 (s, 1H), 7.69 (t, J= 8.1 Hz, 2H), 7.61 (d, J= 7.6 Hz,
1H), 7.54 (t, J= 8.5 Hz, 3H), 7.34 (q, J= 8.1 Hz, 2H), 7.13
(t, J= 7.6 Hz, 1H), 3.86 (m, 2H), 3.55 (t, J= 5.1 Hz, 1H),
3.50 (t, J= 6.2 Hz, 1H), 3.36 (s, 1H), 3.28 (s, 1H), 3.04 (m,
1H), 2.90 (m, 1H), 2.82 (m, 2H), 2.07 (m, 1H), 1.87 (m, 1H);
MS (ESI): m/z 406.21 (M+1)+; Anal. calcd for C21H22F3N3-
O2 C, 62.21; H, 5.47; N, 10.36; found C, 62.22; H, 5.45; N,
10.35.Please cite this article in press as: Mahesh, R. et al., Design, synthesis and evaluation
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diazepan-1-yl) acetamide (5i)
White solid, purity 94% (method A); 1H NMR (CDCl3) d:
9.04 (s, 1H), 7.69 (m, 2H), 7.61 (d, J= 8.0 Hz, 1H), 7.54 (m,
3H), 7.34 (m, 2H), 7.13 (t, J= 8.0 Hz, 1H), 3.90 (m, 2H),
3.55 (d, J= 6.2 Hz, 1H), 3.49 (t, J= 6.2 Hz, 1H), 3.38 (s,
1H), 3.30 (s, 1H), 3.12 (m, 1H), 2.95 (m, 1H), 2.87 (m, 2H),
2.12 (m, 1H), 1.85 (m, 1H); MS (ESI): m/z 406.21 (M+1)+;
Anal. calcd for C21H22F3N3O2 C, 62.21; H, 5.47; N, 10.36;
found C, 62.22; H, 5.45; N, 10.35.
2.5.10. 2-(4-(2-Methoxybenzoyl)-1,4-diazepan-1-yl)-N-
phenylacetamide (5j)
Semi solid, purity 96% (method B); 1H NMR (CDCl3) d: 9.16
(s, 1H), 7.63 (dd, J= 8.6, 1.0 Hz, 1H), 7.54 (m, 1H), 7.34 (m,
3H), 7.23 (m, 1H), 7.11 (m, 1H), 6.99 (m, 1H), 6.92 (dd,
J= 8.3, 4.5 Hz, 1H), 3.95 (m, 1H), 3.84 (m, 1H), 3.81 (s,
3H), 3.45 (m, 1H), 3.35 (s, 2H), 3.26 (m, 1H), 2.99 (m, 1H),
2.81 (m, 4H), 2.04 (m, 1H); MS (ESI): m/z 368.21 (M+1)+;
Anal. calcd for C21H25N3O3 C, 68.64; H, 6.86; N, 11.44; found
C, 68.65; H, 6.87; N, 11.46.
2.5.11. 2-(4-(3-Methoxybenzoyl)-1,4-diazepan-1-yl)-N-
phenylacetamide (5k)
Semi solid, purity 95% (method A); 1H NMR (CDCl3) d: 9.09
(s, 1H), 7.62 (d, J= 7.8 Hz, 1H), 7.53 (d, J= 7.8 Hz, 1H),
7.33 (dd, J= 14.8, 7.8 Hz, 3H), 7.12 (d, J= 7.0 Hz, 1H),
6.97 (m, 3H), 3.86 (m, 1H), 3.81 (s, 3H), 3.78 (m, 1H), 3.55
(m, 2H), 3.34 (s, 1H), 3.26 (s, 1H), 3.01 (m, 1H), 2.88 (m,
1H), 2.80 (m, 2H), 2.04 (m, 1H), 1.85 (m, 1H); MS (ESI): m/
z 368.21 (M+1)+; Anal. calcd for C21H25N3O3 C, 68.64; H,
6.86; N, 11.44; found C, 68.65; H, 6.87; N, 11.46.
2.5.12. 2-(4-(4-Methoxybenzoyl)-1,4-diazepan-1-yl)-N-
phenylacetamide (5l)
Semi solid, purity 99% (method A); 1H NMR (CDCl3) d: 9.11
(s, 1H), 7.57 (m, 2H), 7.40 (d, J= 8.4 Hz, 2H), 7.33 (t,
J= 7.3 Hz, 2H), 7.11 (t, J= 7.3 Hz, 1H), 6.91 (d,
J= 8.4 Hz, 2H), 3.84 (m, 1H), 3.83 (s, 3H), 3.79 (m, 1H),
3.59 (m, 2H), 3.30 (s, 2H), 3.01 (m, 1H), 2.95 (m, 1H), 2.82
(m, 2H), 2.04 (m, 1H), 1.87 (m, 1H); MS (ESI): m/z 368.21
(M+1)+; Anal. calcd for C21H25N3O3 C, 68.64; H, 6.86; N,
11.44; found C, 68.65; H, 6.87; N, 11.46.
2.5.13. 2-(4-(3-Ethoxybenzoyl)-1,4-diazepan-1-yl)-N-
phenylacetamide (5m)
Semi solid, purity 98% (methodB); 1HNMR (CDCl3) d: 9.17 (s,
1H), 7.67 (m, 2H), 7.50 (d, J= 8.4 Hz, 2H), 7.37 (t, J= 7.3 Hz,
2H), 7.21 (t, J= 7.3 Hz, 1H), 6.90 (d, J= 8.4 Hz, 2H), 4.15 (q,
J= 8.0 Hz, 2H), 3.85 (m, 1H), 3.78 (m, 1H), 3.61 (m, 2H), 3.40
(s, 2H), 3.19 (m, 1H), 2.90 (m, 1H), 2.83 (m, 2H), 2.04 (m, 1H),
1.87 (m, 1H), 1.32 (t, J= 8.0 Hz, 3H); MS (ESI): m/z 382.31
(M+1)+; Anal. calcd for C22H27N3O3 C, 69.27; H, 7.13; N,
11.02; found C, 69.24; H, 7.11; N, 11.04.
2.5.14. 2-(4-(2-Ethoxylbenzoyl)-1,4-diazepan-1-yl)-N-
phenylacetamide (5n)
Semi solid, purity 96% (method A); 1H NMR (CDCl3) d: 9.12
(s, 1H), 7.77 (m, 2H), 7.57 (d, J= 8.0 Hz, 2H), 7.37
(t, J= 7.3 Hz, 2H), 7.23 (t, J= 7.3 Hz, 1H), 6.79of 2-(4-(substituted benzoyl)-1,4-diazepan-1-yl)- N-phenylacetamide derivatives
/dx.doi.org/10.1016/j.arabjc.2014.11.008
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3.82 (m, 1H), 3.71 (m, 2H), 3.45 (s, 2H), 3.29 (m, 1H), 2.89
(m, 1H), 2.81 (m, 2H), 2.14 (m, 1H), 1.97 (m, 1H), 1.30 (t,
J= 8.0 Hz, 3H); MS (ESI): m/z 382.31 (M+1)+; Anal. calcd
for C22H27N3O3 C, 69.27; H, 7.13; N, 11.02; found C, 69.24;
H, 7.11; N, 11.04.
2.5.15. 2-(4-(4-Ethoxybenzoyl)-1,4-diazepan-1-yl)-N-
phenylacetamide (5o)
Semi solid, purity 95% (method B); 1H NMR (CDCl3) d: 9.14
(s, 1H), 7.62 (m, 2H), 7.51 (t, J= 8.4 Hz, 2H), 7.37 (m, 2H),
7.21 (d, J= 8.4 Hz, 1H), 6.90 (m, 2H), 4.19 (q, J= 8.1 Hz,
2H), 3.81 (m, 1H), 3.80 (m, 1H), 3.71 (m, 2H), 3.34 (s, 2H),
3.29 (m, 1H), 2.92 (m, 1H), 2.79 (m, 2H), 2.14 (m, 1H), 1.84
(m, 1H), 1.28 (t, J= 8.1 Hz, 3H); MS (ESI): m/z 382.31
(M+1)+; Anal. calcd for C22H27N3O3 C, 69.27; H, 7.13; N,
11.02; found C, 69.24; H, 7.11; N, 11.04.
2.5.16. 2-(4-(3-Methylbenzoyl)-1,4-diazepan-1-yl)-N-
phenylacetamide (5p)
Semi solid, purity 98% (method A); 1H NMR (CDCl3) d: 9.10
(s, 1H), 7.62 (d, J= 7.7 Hz, 1H), 7.52 (t, J= 7.9 Hz, 1H), 7.41
(m, 4H), 7.21 (m, 2H), 7.06 (m, J= 7.3 Hz, 1H), 3.90 (m, 2H),
3.65 (m, 2H), 3.31 (s, 1H), 3.20 (s, 1H), 3.12 (m, 1H), 2.78 (m,
3H), 2.05 (m, 1H), 2.33 (s, 3H) 1.79 (m, 1H); MS (ESI): m/z
352.23 (M+1)+; Anal. calcd for C21H25N3O2 C, 71.77; H,
7.17; N, 11.96; found C, 71.76; H, 7.18; N, 11.95.
2.5.17. 2-(4-(4-Methylbenzoyl)-1,4-diazepan-1-yl)-N-
phenylacetamide (5q)
Semi solid, purity 96% (method B); 1H NMR (CDCl3) d: 9.11
(s, 1H), 7.62 (d, J= 7.7 Hz, 1H), 7.52 (d, J= 7.7 Hz, 1H),
7.32 (m, 4H), 7.21 (m, 2H), 7.11 (t, J= 7.3 Hz, 1H), 3.83
(m, 2H), 3.55 (dd, J= 14.2, 7.9 Hz, 2H), 3.34 (s, 1H), 3.26
(s, 1H), 3.02 (m, 1H), 2.83 (m, 3H), 2.05 (m, 1H), 2.38
(s, 3H) 1.85 (m, 1H); MS (ESI): m/z 352.23 (M+1)+; Anal.
calcd for C21H25N3O2 C, 71.77; H, 7.17; N, 11.96; found C,
71.76; H, 7.18; N, 11.95.
2.5.18. 2-(4-(2-Methylbenzoyl)-1,4-diazepan-1-yl)-N-
phenylacetamide (5r)
Semi solid, purity 97% (method A); 1H NMR (CDCl3) d: 9.10
(s, 1H), 7.62 (m, 1H), 7.53 (m, 1H), 7.32 (m, 3H), 7.20 (m,
3H), 7.12 (m, 1H), 3.92 (m, 2H), 3.37 (m, 4H), 3.06 (s, 1H), 2.87Table 1 Falcipain-2 inhibitor activity proﬁle of ﬁnal compounds 5(
Compound R Inhibition ratec at 10 lm%
5a -H 49
5b m-F 61
5c o-F 60
5d m-Cl 47
5e p-Cl 47
5f o-Cl 36
5g m-CF3 72
5h p-CF3 68
5i o-CF3 50
5j o-OCH3 70
E-64 97.4
c Data are mean of three independent experiments and the deviations a
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MS (ESI): m/z 352.23 (M+1)+; Anal. calcd for C21H25N3O2
C, 71.77; H, 7.17; N, 11.96; found C, 71.76; H, 7.18; N, 11.95.
2.5.19. 2-(4-(4-Ethylbenzoyl)-1,4-diazepan-1-yl)-N-
phenylacetamide (5s)
Semi solid, purity 96% (method C); 1H NMR (DMSO-d6) d:
10.98 (s, 1H), 7.79 (s, 1H), 7.68 (d, J= 7.9 Hz, 2H), 7.38 (m,
2H), 7.28 (m, 3H), 7.11 (t, J= 7.9 Hz, 1H), 4.32 (m, 2H),
3.85 (m, 1H), 3.59 (m, 4H), 3.26 (s, 2H), 2.68 (q, J= 7.6 Hz,
2H), 2.58 (m, 2H), 2.48 (m, 1H), 1.25 (t, J= 7.6 Hz, 3H);
MS (ESI): m/z 366.28 (M+1)+; Anal. calcd for C22H27N3O2
C, 72.30; H, 7.45; N, 11.50; found C, 72.31; H, 7.42; N, 11.51.
2.5.20. 2-(4-(3-Ethylbenzoyl)-1,4-diazepan-1-yl)-N-
phenylacetamide (5t)
Semi solid, purity 94% (method B); 1H NMR (DMSO-d6) d:
10.78 (s, 1H), 7.80 (s, 1H), 7.66 (d, J= 7.9 Hz, 2H), 7.38 (m,
2H), 7.30 (m, 3H), 7.21 (t, J= 7.9 Hz, 1H), 4.30 (m, 2H),
3.75 (m, 1H), 3.57 (m, 4H), 3.46 (s, 2H), 2.66 (q, J= 7.6 Hz,
2H), 2.60 (m, 2H), 2.58 (m, 1H), 1.95 (t, J= 7.6 Hz, 3H);
MS (ESI): m/z 366.28 (M+1)+; Anal. calcd for C22H27N3O2
C, 72.30; H, 7.45; N, 11.50; found C, 72.31; H, 7.42; N, 11.51.
2.6. Enzyme assay
The protocol for the puriﬁcation and refolding of recombinant
protein falcipain-2 as described by Shenai et al. (2000) and
Korde et al. (2008) was followed. In brief, a mixture of
100 mM NaOAc, 10 mM DTT, 6 lM enzyme and 10 lM of
test inhibitors at pH 5.5, 10 mM of ﬂuorogenic substrate ben-
zyloxycarbonyl-Phe-Arg-7-amino-4-methylcoumarin hydro-
chloride (ZFR-AMC) was added and the release of 7-amino-
4-methylcoumarin (AMC) was monitored (excitation 355 nm;
emission 460 nm) over 30 min at RT using Perkin Elmer Victor
3 multi-label counter. Preliminary assays were performed to
determine the percentage inhibition of the enzyme at a concen-
tration of 10 lM based on DMSO as control represented in
Table 1.
2.7. Docking studies
To understand the structural basis for the activities of the
inhibitors and to support the in vitro activity results, wea–t).
Compound R Inhibition rate at 10 lm%
5k m-OCH3 64
5l p-OCH3 55
5m m-OCH2CH3 32
5n o-OCH2CH3 36
5o p-OCH2CH3 30
5p m-CH3 49
5q p-CH3 47
5r o-CH3 48
5s p-CH2CH3 30
5t m-CH2CH3 24
re <5% of the mean value.
of 2-(4-(substituted benzoyl)-1,4-diazepan-1-yl)- N-phenylacetamide derivatives
/dx.doi.org/10.1016/j.arabjc.2014.11.008
6 R. Mahesh et al.studied the binding models of the top four active analogues;
5g, 5h, 5j and 5k with falcipain-2 enzyme using Glide 5.9
(Schrodinger, LLC, New York, NY, 2013) running on maestro
version 9.4 installed in a machine on Intel Xenon W 3565 pro-
cessor and Cent OS Linux Enterprise version 6.3 as the oper-
ating system (Friesner et al., 2004; Halgren et al., 2004). The
crystal structure of falcipain-2 (PDB entry 3BPF) from P. fal-
ciparum was retrieved from the Protein Database Bank with a
resolution of 2.9 A˚. The downloaded FP-2 protein carries four
chains named A, B, C, and D; complexed with epoxysuccinate
E64 (Wang et al., 2000). The catalytic triad of Cys 42, Asn 173
and His 174 is located in the cleft between the two structurally
distinct domains (Wang et al., 2014). Protein preparation mod-
ule of Schrodinger suite was used for protein preparation. Pro-
teins were pre-processed separately by deleting the substrate
co-factor as well as the observed water molecules were
removed from the coordinate set, followed by optimization
of hydrogen bonds. Charge and protonation state was assigned
and energy was minimized with Root Mean Square Deviation
(RMSD) value of 0.3 A˚ using Optimized Potentials for Liquid
Simulations-2005 (OPLS-2005) force ﬁeld (Jorgensen et al.,
1996). Potential of non-polar parts of receptors was softened
by scaling van der Walls radii of ligand atoms by 1.00 A˚ to
generate the grid. Analogues and Standard Drug E-64 struc-
tures were drawn using ChemSketch and converted to 3D
structure with the help of 3D optimization tool. LigPrep mod-
ule was used to optimize the geometry of the drawn ligands.
3. Results and discussion
Existing falcipain-2 inhibitors, (Desai et al., 2004; Li et al., 2009)
were used as a template for making a pharmacophore model for
falcipain-2 inhibitors, and some of the compounds (I–VIII),
which possess moderate to potent activities are represented in
Fig. 2. Among the represented compounds, particular imineO
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enzyme by covalent interactions.
The most common features present in the aforementioned
falcipain-2 inhibitors are, an aromatic residue (monocyclic/
bicyclic) which is attached to the hydrophobic moiety; com-
monly an aromatic residue through a hydrogen bond donor
and acceptor atom(s) as linker. The distance between the aro-
matic residue and the hydrophobic group ranged from 9 to
14 A˚. The hydrogen bond donor (HBD) and hydrogen bond
acceptor (HBA) atom(s) are present as either in heterocyclic/
alicyclic or open chain form. The numbers of hydrogen bond
donor and acceptor atoms range from 0 to 2 and 2 to 6, respec-
tively. The reported molecules are basic in nature due to 2 or
3 amino moiety. By considering these common features as
pharmacophore for falcipain-2 inhibitors, a pharmacophore
model was built as shown in Fig. 3. Among the broad range
of heterocyclic templates particularly, the piperazine core is
found as the most encouraging leading heterocyclic ring, pres-
ent in a number of drugs and clinical candidates that address a
broad spectrum of serious targets (Han et al., 2012). Therefore,
initially we synthesized some derivatives based on piperazine
nucleus, and tested in vitro against falcipain-2 enzyme; unfor-
tunately, the insigniﬁcant activity of the compounds (unpub-
lished observation), prompted us to focus our efforts to
increase the ring size especially, on utilizing 1,4-diazepam as
a core nucleus (Ettari et al., 2009; Micale et al., 2006), with
the aim of improving the drug like proﬁle of this novel class
of compounds, as shown by basic structure 5(a–t) in Scheme 1.
The least energy conformation (three minimum energy con-
formations for each compound) for each designed compound
was generated by ACDLABS-12.0 product version 12.01/3D
viewer (CHARMM parameterizations), and the pharmaco-
phoric distances were measured from the centroid of an aro-
matic residue to a hydrophobic residue. The observed
distances between the pharmacophoric elements of all theN
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Figure 3 Pharmacophoric features for falcipain-2 inhibitors.
Synthesis of 2-(4-(substituted benzoyl)-1,4-diazepan-1-yl)-N-phenylacetamide derivatives 7designed compounds are in agreement with our proposed
pharmacophore model. To achieve the better pharmacokinetic
proﬁle, Lipinski’s Rule of Five (Lipinski et al., 1997) was
adopted for the designed molecules. Lipophilicity is an impor-
tant parameter to be considered while designing ligand to man-
ifest drug-like behavior. Thus, LogP values of all the designed
molecules were calculated utilizing JME Molecular Editor
(Courtesy of Peter Ertl, Novartis).
The target compounds were prepared as outlined in
Scheme 1. First, compound 4 was synthesized in multi-gram
scale from the starting material aniline in a sequence of reac-
tions. Chloroacetyl chloride was subjected to nucleophilic sub-
stitution reaction with aniline, which afforded compound 2.
This intermediate was reacted with N-Boc protected homopip-
erazine, to obtain compound 3. Subsequently, deprotection of
the Boc group with triﬂuroacetic acid furnished the intermedi-
ate 2-(1,4-diazepan-1-yl)-N-phenylacetamide 4. This key
intermediate was coupled with appropriate carboxylic acidsTable 2 Physical constants of 2-(4-(substituted benzoyl)-1,4-diazep
Compound R Molecular Weight Mol
5a -H 337.44 C20H
5b m-F 355.40 C20H
5c o-F 355.40 C20H
5d m-Cl 371.86 C20H
5e p-Cl 371.86 C20H
5f o-Cl 371.86 C20H
5g m-CF3 405.41 C21H
5h p-CF3 405.41 C21H
5i o-CF3 405.41 C21H
5j o-OCH3 367.44 C21H
5k m-OCH3 367.44 C21H
5l p-OCH3 367.44 C21H
5m m-OCH2CH3 381.46 C22H
5n o-OCH2CH3 381.46 C22H
5o p-OCH2CH3 381.46 C22H
5p m-CH3 351.44 C21H
5q p-CH3 351.44 C21H
5r o-CH3 351.44 C21H
5s p-CH2CH3 365.40 C22H
5t m-CH2CH3 365.46 C22H
a Yields refer to isolated pure compounds.
b Log P values are calculated by using JME Molecular Editor (Courtes
Table 3 Results of docking simulations for the most active molecu
Name of ligand G-score Lipophil
5g 6.405 3.426
5h 6.380 3.509
5j 6.404 3.720
5k 6.128 3.744
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pyl)-3-ethylcarbodiimide hydrochloride (EDCÆHCl) and 1-
hydroxybenzotriazole (HOBt) under nitrogen atmosphere to
afford target compounds 5(a–t). Synthesized compounds were
isolated as pure and characterized by 1H NMR, mass spectros-
copy, HPLC and elemental analysis. The analytical and spec-
tral data of the compounds conﬁrmed the structures and
purities of the ﬁnal compounds.
All synthesized compounds were evaluated for their in vitro
falcipain-2 inhibitor activity. Several compounds showed sig-
niﬁcant inhibitory activity (>60%), against falcipain-2 at
10 lM presented in Table 1, and their chemical structures
and physical constants are shown in Table 2.
Retaining the common 2-(4-(substituted benzoyl)-1,4-diaze-
pan-1-yl)-N phenylacetamide framework, compounds 5a, 5b
were screened, initially. Fortunately, these two compounds
5a and 5b exhibited inhibitory activity against falcipain-2
enzyme at 10 lM concentrations with inhibition values of
49% and 61%, respectively. Based on its moderate potency
and synthetic feasibility, compound 5b served as a solid start-
ing point for the future drug discovery program. Thus, various
substitutions were introduced around the scaffold based on 5b
speciﬁcally in the aromatic moiety. The effect of the ﬂuorine
group, an electron withdrawing substituent, was investigated
at position 2 on the phenyl moiety (compound 5c). This
modiﬁcation did not result in any improved potency, andan-1-yl)-N-phenylacetamide derivatives 5(a–t).
ecular Formula % Yielda m.p. (C) LogPb
23N3O2 62 Semi solid 1.79
22FN3O2 82 125–127 1.95
22FN3O2 68 118–120 1.95
22ClN3O2 81 Semi solid 2.35
22ClN3O2 65 Semi solid 2.35
22ClN3O2 62 Semi solid 2.35
22F3N3O2 68 122–124 2.71
22F3N3O2 61 156–158 2.71
22F3N3O2 61 140–142 3.22
25N3O3 64 Semi solid 1.66
25N3O3 73 Semi solid 1.66
25N3O3 87 Semi solid 1.66
27N3O3 66 Semi solid 2.0
27N3O3 71 Semi solid 2.0
27N3O3 71 Semi solid 2.0
25N3O2 66 Semi solid 2.27
25N3O2 81 Semi solid 2.27
25N3O2 62 Semi solid 2.27
27N3O3 70 Semi solid 2.69
27N3O2 79 Semi solid 2.69
y of Peter Ertl, Novartis).
les using Glide software.
ic EvdW H bond XP Electro
1.583 0.7663
1.582 0.7637
2.439 0.5968
2.096 0.5546
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Figure 4 (A–D) Predicted binding poses of 5g, 5h, 5j, 5k respectively docked to chain A of falcipain-II protein (3BPF.pdb). The red
dashed line represents the possible hydrogen bond and green dashed line represents the possible hydrophobic interaction.
Figure 5 Best docked pose of E-64 inside falcipain-2. The pink
dashed line represents the possible hydrogen bond and green
dashed line represents the possible hydrophobic interaction.
8 R. Mahesh et al.compound exhibited 60% enzyme inhibition value close to the
compound 5b. Placement of another electron withdrawing sub-
stituent such as chloro in the aromatic ring, generated mole-
cules (5d, 5e, 5f) with less potency (47% inhibition by 5d and
5e, and 36% by 5f). When a strong electron withdrawing
group, triﬂuoromethyl was introduced at the 3 position to
get the compound 5g (72% inhibition) and position 4 to get
the compound 5h (68% inhibition), both compounds showed
higher potency than the hit compound 5b. However, investiga-
tion of a triﬂuoromethyl group at the 2 position (compound 5i)
of the phenyl ring showed lesser potency (50% inhibition)
compared to compound 5b.
Consequently, a methoxy group, an electron releasing sub-
stituent was introduced at 2 and 3 positions of the phenyl ring
resulting in compounds 5j and 5k, with improved inhibition
potency (70% and 64%), greater than the hit compound 5bPlease cite this article in press as: Mahesh, R. et al., Design, synthesis and evaluation of 2-(4-(substituted benzoyl)-1,4-diazepan-1-yl)- N-phenylacetamide derivatives
as a new class of falcipain-2 inhibitors. Arabian Journal of Chemistry (2014), http://dx.doi.org/10.1016/j.arabjc.2014.11.008
Synthesis of 2-(4-(substituted benzoyl)-1,4-diazepan-1-yl)-N-phenylacetamide derivatives 9from this series. Attachment of the methoxy group in the 4
position of the phenyl ring gave rise to compound 5l, with inhi-
bition potency (55%), which was lesser than that of 5b. Com-
pounds 5m, 5n and 5o achieved by replacement of the methoxy
group with the ethoxy group lose (32%, 36% and 30%)
potency markedly. Replacement of the methoxy group in the
phenyl ring with another weak electron releasing group such
as methylene (5p, 5q and 5r) at 2, 3 and 4 positions and the eth-
ylene (5s and 5t) group at 3 and 4 positions leads to a decrease
in the potency.
This discussion clearly indicates that the strong electron
withdrawing group (triﬂuoromethyl) at 3 and 4 positions and
a strong electron releasing group (methoxy) at 2 and 3 posi-
tions generated compounds that displayed marked inhibition
as evidenced by compounds 5g, 5h, 5j, and 5k compared to
the non-substituted derivatives i.e., compound (5a). Higher
homologation of electron releasing groups, methoxy to ethoxy
(5m, 5n, 5o) and methylene to ethylene (5s, 5t) in the phenyl
ring generated compounds with lesser inhibition.
The prepared ligands were docked with proteins using extra
precision mode (XP). The best docked pose obtained from
Glide was analyzed. Results of docking simulations using
Glide are summarized as XP Gscore, lipophilic energy, H-
bond energy and electrophoretic energy in Table 3. Compari-
son of interacting residues of these analogues (5g, 5h, 5j, 5k)
shows that the amino acids Ala 175, Trp 43, Ile 85, Leu 84,
Cys 42, Trp 206, Val 152 and Asp173 of falcipain-II protein
are most commonly involved as shown in Fig. 4(A–D). Among
these, the residue Asp 173 was the hydrogen bonding common
interacting residue of falcipain-II with ligands (5g, 5h, 5j, 5k).
Compound 5g showed eight hydrophobic interactions, Ala
175, Trp 43, Ile 85, Leu 84, Leu172, Cys 42, Trp 206, Val
152; two hydrogen bonds, Gln 36 (2.08 A˚), Asn 173 (2.19 A˚).
Compound 5h showed nine hydrophobic interactions, Ala
175, Trp 43, Ile 85, Leu 84, Leu 172, Cys 42, Trp 206, Val
152, Ile 84; two hydrogen bonds, Asn 173 (2.25 A˚), Gln 36
(2.27 A˚). Compound 5j showed seven hydrophobic interac-
tions, Ala 175, Trp 43, Ile 85, Leu 84, Cys 42, Trp 206, Val
152; two hydrogen bonds, Asn 173 (2.34 A˚), Hip 174
(2.06 A˚). Compound 5k showed nine hydrophobic interac-
tions, Ala 175, Trp 43, Ile 85, Leu 84, Leu 172, Cys 42, Trp
206, Val 152, Val 150; three hydrogen bonds, Asn 173
(2.51 A˚), Hip 174 (1.93 A˚), Gln 83 (2.49 A˚).Table 4 In-silico predicted admet properties of selected compounds
Properties 5g 5h
LogSd 4.20 4.20
LogBBe (probability) 0.983 0.982
Human oral absorption (%)f 97.5 97.2
Caco-2 permeabilityg 1.103 1.103
AMES toxicity (probability) Non toxic (0.707) Non toxic (0.707)
Carcinogens (probability) Non-carcinogen
(0.8372)
Non-carcinogens
(0.8372)
Acute oral toxicityh (probability) III 0.6166 III 0.6166
d Predicted aqueous solubility in moles/liter.
e Predicted brain/blood partition coefﬁcient.
f Percentage of human oral absorption.
g Predicted apparent Caco-2 cell permeability (nm/s).
h Category III includes compounds with LD50 values [500 mg/kg butn5
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removing co-crystallized ligand E-64 from the active site and
subjecting it again to dock into the binding pocket in the con-
formation found in the crystal structure. It is important to note
that E-64 is a covalent inhibitor of several cysteine proteases
and is potent non-selective due to the formation of covalent
bond with the active site thiol (Li et al., 2009; Schiefer et al.,
2013). Therefore, to validate the docking protocol, we used
E-64 with an open epoxide ring as reported in the literature
(Mugumbate et al., 2013). Furthermore, a set of studies were
performed to compute the RMSD value between the pose of
co-crystallized inhibitor present in the enzyme and its best
ranked pose (Fig. 5), in the protein. As a result, the RMSD
value calculated for co-crystallized ligand, E 64 was <2 A˚
against the target enzyme. The best scoring pose of the refer-
ence drug inside the FP-2 showed that interactions are in
resemblance with the reported X-ray pose interactions (Kerr
et al., 2009). These results suggested that our docking proce-
dure, and software protocol could be relied on to predict the
experimental binding mode of the designed analogues.
As discussed earlier, physicochemical properties such as
molecular weight (180–500), log Po/w (0.4 to 5.6), of all the
designed analogues follow Lipinski’s Rule of Five. Further-
more, Qik–prop module of Schrodinger, and online software
admetSAR (http://www.admetexp.org/predict/), were used to
generate in silico pharmacokinetics and physicochemical
parameters for compounds 5g, 5h, 5j and 5k in order to esti-
mate their drug-likeness properties. The recommended range
(Ntie-Kang et al., 2013; Cheng et al., 2012) of some physico-
chemical and pharmacokinetic parameters, which plays an
important role to both pre-clinical research and clinical devel-
opment, such as: logS (6.0 to 0.5), logBB (3.0 to 1.0), %
Human oral absorption (625% is poor and P80% is high)
was predicted (Table 4). In addition, AMES toxicity, acute
oral toxicity and carcinogenicity were also predicted and repre-
sented as qualitative terms with probability (in bracket) in
Table 4. Range of Caco-2 cell permeability gives a view to
select a molecule as lead compound at early stage by determin-
ing the capability to transport about across the cell membrane
of the gut. The physicochemical properties and in silico pre-
dicted ADMET properties as mentioned in Tables 2 and 4,
for selected analogues are in the acceptable range of druggable
proﬁle..
5j 5K Range for drug likeness
3.04 3.28 6.5–0.5
0.953 0.971 –
95.8 96.0 P80% is high, 625% is poor
1.255 0.935 –
Non toxic (0.764) Non toxic (0.789) –
Non-carcinogens
(0.9062)
Non-carcinogens
(0.9104)
–
III 0.7543 III 0.7813 –
000 mg].
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10 R. Mahesh et al.Although, representatives of this new series did not exhibit
strong falcipain-2 activities as compared to the existing non-
peptidic FP-2 inhibitors such as chalcones (Li et al., 1995;
Liu et al., 2001), which are biosynthetic precursors of
ﬂavonoids, thiosemicarbazones (Chiyanzu et al., 2003) and
isoquinolines (Sajid and McKerrow, 2002; Batra et al.,
2003). However, this work shows that indirect drug design pro-
tocol can be successfully expedited for the discovery of small
molecule cysteine protease inhibitors. Overall, the discussed
efforts toward the design of inhibitors of the malarial cysteine
proteases clearly demonstrate the effectiveness of combining
computational techniques with organic synthesis in delivering
novel potential inhibitors and in providing directions for
further improvements.
4. Conclusion
In summation, a series of 2-(4-(substituted benzoyl)-1,4-diaze-
pan-1-yl)-N-phenylacetamide with twenty novel derivatives,
using ligand based approach were synthesized and screened
for falcipain-2 inhibition. The structures of the compounds
were assigned on the basis of 1H NMR and mass spectral data.
The preliminary SARs indicate that, overall, the compounds
having 3-F (5b), 3-CF3 (5g), 4-CF3 (5h), 2-OCH3 (5j) and 3-
OCH3 (5k) substituent in the aromatic ring displayed marked
inhibition. Compound 5g is the most potent compound from
this series, with lesser toxicity predicted by softwares (admet-
SAR and QikProp module of Schrodinger), and it can be
utilized as a potential lead compound in the designing of
new candidates to optimize the inhibitory potencies of this
class of compounds, with potent antimalarial activity. Docking
result provided the fundamental structural information to
maintain the inhibitory activity, and was helpful for future
inhibitor design. Moreover, to get the conclusive results, plas-
modia study has to be done which will be the futuristic exten-
sion of the work. Thus, the present approach could be an
excellent starting point for the development of novel cysteine
protease inhibitors, and in general, for the development of
new drugs for malaria.
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